Two Sigma Advisers LP Sells 74,800 Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS)

Two Sigma Advisers LP cut its position in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) by 87.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,800 shares of the company's stock after selling 74,800 shares during the quarter. Two Sigma Advisers LP owned about 0.07% of Sensus Healthcare worth $75,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Renaissance Technologies LLC boosted its stake in Sensus Healthcare by 5.3% in the 4th quarter. Renaissance Technologies LLC now owns 430,934 shares of the company's stock worth $2,982,000 after purchasing an additional 21,600 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Sensus Healthcare by 30.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company's stock worth $2,620,000 after buying an additional 88,953 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Sensus Healthcare by 81.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company's stock valued at $1,039,000 after buying an additional 67,269 shares during the last quarter. Marshall Wace LLP increased its position in shares of Sensus Healthcare by 99.6% during the fourth quarter. Marshall Wace LLP now owns 132,286 shares of the company's stock valued at $915,000 after acquiring an additional 65,994 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC increased its position in shares of Sensus Healthcare by 65.1% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 93,248 shares of the company's stock valued at $645,000 after acquiring an additional 36,785 shares in the last quarter. 25.30% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on SRTS shares. Lake Street Capital lowered their price objective on Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Maxim Group reduced their price objective on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a report on Monday, May 19th. Wall Street Zen lowered Sensus Healthcare from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Sensus Healthcare in a research note on Friday, April 4th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $11.67.

Sensus Healthcare Price Performance

NASDAQ SRTS opened at $4.92 on Monday. The business's fifty day moving average price is $4.63 and its 200-day moving average price is $5.85. The stock has a market capitalization of $80.91 million, a price-to-earnings ratio of 12.30 and a beta of 1.32. Sensus Healthcare, Inc. has a 1-year low of $4.01 and a 1-year high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.20). The firm had revenue of $8.34 million during the quarter, compared to the consensus estimate of $7.23 million. Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. Equities research analysts anticipate that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.

Sensus Healthcare Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Want to see what other hedge funds are holding SRTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.